media – Page 106 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Morocco Medical Expo

Organizer: ATELIER VITA, Morocco Date: April 10-13, 2025 Venue: Parc d’Exposition Mohammed VI, El Jadida, Route Nationale 1, vers Azemmour, Région Doukala Abada, 24000 – El Jadida Exhibition Hall: Parc d’Exposition Mohammed VI a El Jadida Product range: Dental Equipment: Dental comprehensive treatment equipment, dental laser treatment devices, dental X-ray machines, dental instruments, and materials Finished Pharmaceutical Products: Various over-the-counter and prescription drugs, traditional Chinese medicines, western medicines, new drugs, special-effect drugs, biopharmaceuticals, herbal medicine raw materials, various APIs, chemical pharmaceuticals, pharmaceutical intermediates Active Pharmaceutical Ingredients (APIs): Chemical pharmaceutical raw materials, pharmaceutical intermediates, auxiliaries, fine chemicals, antibiotics, chiral compounds, synthetic organic chemicals Pharmaceutical Industry: Production equipment and technologies for pharmaceuticals Exhibition Introduction: The Morocco Medical Expo is one of the most significant and influential medical and pharmaceutical exhibitions in North Africa. The event not only attracts local exhibitors from Morocco but also draws international medical companies and institutions ...
- Source: drugdu
- 5,782
- July 12, 2024
FDA Approves Arcutis Biotherapeutics’ Zoryve to Treat Patients with Mild to Moderate Atopic Dermatitis

By Don Tracy, Associate Editor Zoryve is a steroid-free, once-daily treatment shown to offer rapid disease clearance and significant itch reduction for patients with mild to moderate atopic dermatitis. The FDA has approved Arcutis Biotherapeutics’ supplemental New Drug Application (sNDA) for Zoryve (roflumilast) cream 0.15% for mild to moderate atopic dermatitis (AD) in adults and children over six years of age. According to the company, the treatment is steroid-free and moves quickly to clear the disease, resulting in significant itch reduction. The approval was based on results from three Phase III studies, a Phase II dose-ranging study, and two Phase I pharmacokinetic studies.1 “The chronic nature of AD coupled with the disease instability often leaves patients and caregivers feeling that they are constantly chasing their AD flares,” said Lawrence F. Eichenfield, MD, professor of dermatology and pediatrics, vice chair, department of dermatology, UC San Diego School of Medicine, INTEGUMENT study ...
- Source: drugdu
- 78
- July 12, 2024
Amylyx Aims to Help Patients With a Novel GLP-1 Drug, But Not the Way You Think

Unlike GLP-1 agonist drugs marketed for weight loss, new Amylyx Pharmaceuticals drug avexitide blocks its target receptor. Amylyx plans to advance this GLP-1 antagonist into Phase 3 testing for post-bariatric hypoglycemia, a rare condition in which blood sugar levels drop precipitously. By Frank VinluanBefore GLP-1 drugs became a wildly popular pharmacologic way to treat obesity, bariatric surgery was a top option for those seeking a medical intervention for losing weight. While this procedure is effective for weight loss, it turns out that changing the structure of the gut can lead to a debilitating disorder in some patients. Amylyx Pharmaceuticals, months removed from a clinical trial failure that shattered its prospects in neurodegeneration, is now planting a flag in metabolic disease with the acquisition of a Phase 3-ready drug for this rare disorder with no FDA-approved therapies. The drug comes from Eiger BioPharmaceuticals, which last month sold off its assets in ...
- Source: drugdu
- 79
- July 12, 2024
Arcutis bags FDA approval for atopic dermatitis cream after delay

Arcutis has won its third US Food and Drug Administration (FDA) approval for Zoryve (roflumilast) cream in two years, with the latest indication meant for adults and some children with atopic dermatitis. The FDA has approved the once-daily topical cream for mild to moderate atopic dermatitis in patients aged six years and older. Zoryve, a phosphodiesterase-4 (PDE4) inhibitor, was approved as a cream in July 2022 for the treatment of plaque psoriasis for patients aged 12 and older, and October 2023 for children aged 6-11 with psoriasis. The initial date for the label expansion in atopic dermatitis was set for 7 June 2024, but the decision was delayed by several days, with Arcutis releasing a statement on 9 June saying there had been no request for new information from the regulator at the time. The approval is supported by positive data from three Phase III studies, a Phase II dose-ranging ...
- Source: drugdu
- 80
- July 12, 2024
NICE recommends Ebglyss for atopic dermatitis patients

England’s National Institute for Health and Care Excellence (Nice) has recommended Almirall’s Ebglyss (lebrikizumab) for patients with moderate to severe atopic dermatitis, giving NHS patients another biological therapy option. In line with NICE guidelines, the NHS will now have 90 days to make the treatment available to patients. Patients over 12 years of age who have not responded to or are not able to take systemic immunosuppressants will be eligible for the therapy, as per a 10 July press release. Monoclonal antibody Ebgylss will join Sanofi / Regeneron’s Dupixent (dupilumab) and Leo Pharma’s Adbry (tralokinumab) as interleukin-targeting options for treating the skin condition. The Janus kinase (JAK) inhibitors Cibinqo (abrocitinib), Olumiant (baricitinib), and Rinvoq (upadacitinib) developed by Pfizer, Eli Lilly, and AbbVie, respectively, are also recommended by NICE. Atopic dermatitis, also known as atopic eczema, is an inflammatory skin condition characterised by intense itching. It has an estimated prevalence of ...
- Source: drugdu
- 68
- July 12, 2024
UK DRI and NHS collaborate on digitally enabled dementia care platform

by Jen Brogan | 10th Jul 2024 | News Around one in five dementia hospitalisations are due to potentially preventable causes The UK Dementia Research Institute (UK DRI), in collaboration with the NHS, aims to conduct a new two-year study to prepare its digitally-enabled dementia care platform, Minder, to be integrated into health and social care services. Funded by LifeArc, the study will enable digital care for people living with dementia while empowering the NHS and social care services to provide care of the highest quality in patients’ own homes. Estimated to affect 944,000 people in the UK, dementia is a general term for the impaired ability to remember, think, or make decisions that affects everyday life. Developed by the UK DRI Centre for Care Research and Technology, Minder is a home monitoring platform that harnesses artificial intelligence (AI) and digital technology and is integrated with public services to detect ...
- Source: drugdu
- 112
- July 12, 2024
Institutions to lead £1.7m-funded network to support people at risk of dementia

The neurodegenerative condition currently affects more than 944,000 people in the UK University College London (UCL) and the University of Exeter are set to co-lead a new national Dementia Network Plus initiative supported by more than £1.7m in funding. The Sustainable Prevention, Innovation and Involvement NETwork (SPIINNET) will help to reduce dementia risk and improve people’s experiences of living with dementia by supporting new projects and engaging with communities. Affecting more than 944,000 people in the UK, dementia is a neurodegenerative condition that affects the ability to remember, think or make decisions in everyday life. The new network will combine researchers from 14 universities with specialist organisations, including King’s College London, the University of Plymouth, Bangor, Cardiff Metropolitan, East Anglia, Northampton, Nottingham, Oxford, Southampton, Stirling, Strathclyde, Sunderland and Worcestershire. SPIINNET aims to utilise existing networks and umbrella organisations to deliver a programme to create connections between the experience, knowledge and ...
- Source: drugdu
- 98
- July 12, 2024
【EXPERT Q&A】What are the differences between the Class II Medical Device Registration and the Class III Medical Device License? What are the application processes for each?

Drugdu.com expert’s response: There are significant differences between the Class II medical device registration and the Class III license in various aspects, mainly embodied in the risk levels of medical devices covered, management requirements, and application procedures. Below are detailed distinctions and their respective application procedures: 1.Differences Risk Levels and Management Requirements Class II Medical Devices: Pose moderate risks and require strict control management to ensure their safety and effectiveness. The safety and efficacy of these devices must be regulated to prevent unnecessary risks to patients or users during use. Examples include X-ray machines, B-mode ultrasound scanners, microscopes, biochemical analyzers, etc. Class III Medical Devices: Represent the highest level of medical devices and are subject to the strictest control. These devices are often implanted into the human body or used to support or sustain life, and their failure can cause severe harm or even death to patients. Therefore, their safety ...
- Source: drugdu
- 128
- July 12, 2024
Philips recall of imaging coils tied to 12 injuries

Dive Brief Philips has recalled several models of Sense XL Torso coils due to the risk of the devices heating up during MRI scans and burning patients. Philips updated the instructions for six models of Sense XL Torso coils used with 1.5T and 3.0T MRI scanners, according to a recall notice posted Monday by the Food and Drug Administration. The recall does not require products to be removed from facilities or where devices are sold. Twelve reported injuries have been associated with the recall, the FDA said. No deaths were reported. Dive Insight Philips’ latest recall is yet another safety problem for the company, which has spent more than three years managing a recall of over 15 million respiratory devices. The company has had recent issues with imaging machines. In November, Philips recalled certain MRI scanners because of the risk of machines exploding. The FDA said at the time that ...
- Source: drugdu
- 77
- July 11, 2024
Masimo offered up to $950M for consumer business

Dive Brief Masimo received a non-binding offer on July 2 from a company prepared to buy its consumer business for a range of from $850 million to $950 million. The offer, which Masimo disclosed Monday in a federal filing, is less than the price the unnamed partner proposed in a term sheet in May and less than what Masimo paid to expand in the consumer market in 2022. Masimo plans to negotiate for a higher price. The update comes as Masimo prepares for an annual meeting at which an activist shareholder will try to remove the company’s CEO and founder Joe Kiani from the board of directors. Dive Insight Masimo, a pulse oximetry specialist, expanded in the consumer space by acquiring Sound United for $1 billion in 2022. The company saw Sound United’s consumer channel expertise as a way to accelerate its expansion beyond healthcare settings. However, Masimo’s share price ...
- Source: drugdu
- 107
- July 11, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.